Aptuit LLC has initiated a growth program for 2016 to increase discovery, Chemistry, Manufacturing and Controls (CMC), and non-clinical development capabilities. Aptuit will hire an additional 90 scientists at its facilities in Oxford, UK and Verona, Italy and will invest $16 million in facility upgrades and equipment to enhance development capabilities.
 
For its Drug Design & Discovery services, additional capacity and targeted investments will be made in hit identification solutions, translational and biomarkers capabilities and late lead optimization strategies.
 
CMC will be expanded with additional technologies in clinical manufacturing, in particular to its tableting and encapsulating; increasing the footprint and capabilities of its formulation development facilities to expand capabilities to develop poorly soluble products; and specific investments in quality control and material sciences.
 
Dr. Goldman, Aptuit’s chief executive officer, said, “Customers have noted our unique capabilities in integrated discovery, integrated CMC and integrated development. We are delighted to leverage our core scientific expertise and respond to this increase in demand especially in discovery and various CMC disciplines.” He continued, “Our growth program leads to a significant increase in capacity allowing us to deliver more high quality integrated CMC and help our customers increase their chances of successful IND filing. We will deliver these services from our fully integrated R and D facilities in Verona, Italy, and Oxford, UK.”